VERAXA Biotech Appoints Dr. Christoph Erkel as CSO to Advance BiTAC Platform

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics researcher Christoph Erkel, Ph.D., as Chief Scientific Officer, reinforcing the company’s focus on advancing its proprietary BiTAC(R) technology platform as it prepares its lead oncology programs for clinical development. The announcement comes at a time when the biotechnology company is moving several elements of its research pipeline forward while expanding its scientific and regulatory capabilities. Dr. Erkel previously served as Vice President of Research & Development, where he helped oversee development of VERAXA’s antibody therapeutics portfolio. In his new role, he will lead scientific strategy across the company’s BiTAC(R) platforms and broader oncology pipeline while directing efforts to accelerate product candidates toward clinical trials.

VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics. The company’s lead BiTAC(R)-TCE program recently received regulatory feedback from Germany’s Paul-Ehrlich-Institute, providing additional clarity for development. Investors are closely watching companies developing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity. The leadership change strengthens VERAXA’s position as it advances its BiTAC(R) technology platform, which aims to create safer and more effective cancer treatments. The company’s press release includes a link to read more about the announcement at the BillionDollarClub website, which provides further details on the scientific leadership and pipeline progress.

BillionDollarClub (“BDC”) is a specialized communications platform that focuses on the biggest and brightest companies covered by IBN. It is one of over 75 brands within the Dynamic Brand Portfolio @ IBN that delivers a range of services, including access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BDC is uniquely positioned to serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. For more information, visit the BillionDollarClub website.